Biochemical and Histopathological Investigation of Resveratrol, Gliclazide, and Losartan Protective Effects on Renal Damage in a Diabetic Rat Model

• Published in: Analytical and quantitative cytopathology and histopathology Vol. 37; no. 3; p. 187
• Main Authors: Ezel, Tasdemir, Kocyigit, Yuksel, Deveci, Engin, Atamer, Yildiz, Sermet, Abdurrahman, Uysal, Ersin, Aktaş, Ayfer, Yavuz, Dilek
• Format: Journal Article
• Language: English
• Published: United States 01-06-2015
• Subjects: Angiotensin II Type 1 Receptor Blockers - pharmacology; Animals; Antioxidants - pharmacology; Diabetes Mellitus, Experimental - complications; Diabetes Mellitus, Type 1 - complications; Diabetic Nephropathies - prevention & control; Enzyme-Linked Immunosorbent Assay; Gliclazide - pharmacology; Hypoglycemic Agents - pharmacology; Immunohistochemistry; Kidney - drug effects; Losartan - pharmacology; Male; Rats; Rats, Wistar; Stilbenes - pharmacology

To compare the protective effects of resveratrol, gliclazide, and losartan, at biochemical and histopathological levels, on the rat kidney with experimentally induced type 1 diabetes.
A total of 35 adult male Wistar rats were divided into control, diabetic, diabetic gliclazide, diabetic resveratrol, and diabetic losartan groups. For biochemical analysis, based on one of the kidneys, superoxide dismutase, malondialdehyde, and catalase were used for measurement. The other kidney was stained for histochemical and immunohistochemical markers and examined by light microscopy.
Nephropathy due to diabetes was developed at the end of the third week in the diabetic group: in the glomeruli, contraction from Bowman distance, diffuse mesangial matrix increasing and tubular dilation, and cytoplasmic vacuolar changes were observed. In tubulointerstitial areas, some tubular structures, an increased expression of VEGF was observed.
As a result, in diabetic rats, the effects of gliclazide, resveratrol, and losartan cure were equivalent to each other according to the parameters which were followed. Resveratrol, gliclazide, and losartan significantly protected renal glomeruli and the proximal and distal tubules.